Newscasting from ESC 2024 - Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration
An analysis of the SCORED trial from the European Society of Cardiology (ESC) Congress 2024 highlights the effect of the SGLT1/2 inhibitor sotagliflozin (Inpefa) on heart failure outcomes based on diabetes duration.
Results of the analysis, which were presented by Rahul Aggarwal, MD, of Brigham and Women’s Hospital, indicate use of the agent was associated with consistent benefit on the primary endpoint regardless of diabetes duration, with the magnitude of benefit increased as diabetes duration increased.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
